Abstract: A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions containing the thienopyridine compound can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.

Abstract: An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue (mutated OrfB), and is capable of producing eicosapentaenoic acid (EPA), and the like.

Abstract: An object of the present invention is to provide a microorganism that efficiently produces a PUFA and a method for producing a PUFA using the microorganism. The present invention relates to a microorganism capable of producing a polyunsaturated fatty acid (PUFA), in which a gene encoding an exogenous polyketide synthase dehydratase (PS-DH) domain having a higher activity against 3-hydroxyhexanoyl acyl carrier protein (3-hydroxyhexanoyl ACP) than an endogenous FabA-like ?-hydroxyacyl-ACP dehydratase (FabA-DH) domain has been introduced into a microorganism having a PUFA metabolic pathway, and the like.

Abstract: The disclosure relates to a cervical spine fixation apparatus comprising: a body; a spacer; and a frame which is positioned on the lateral side of the spacer and couples with the spacer, wherein the frame has a coupling part for coupling with the body, and the body comprises a hole in which the coupling part of the frame is inserted. Or, the disclosure relates to a cervical spine fixation apparatus comprising: a body; and a spacer having a coupling part, wherein the body comprises a hole in which the coupling part is inserted, and the spacer moves with respect to the body.

Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.

Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.

Abstract: An object of the present invention is to provide a crystal of an amino acid salt of HMB which is easy to handle and has high solubility, and to provide a method for producing the same. According to the present invention, the crystal of an amino acid salt of HMB can be precipitated by dissolving an amorphous amino acid salt of HMB in a solvent containing alcohol and stirring or allowing the solvent to left stand. In addition, the crystal of an amino acid salt of HMB can be precipitated by concentrating an aqueous HMB solution of an amino acid salt which has a pH of 2.5 to 11.0.

Abstract: An object of the present invention is to provide a crystal of an amino acid salt of HMB which is easy to handle and has high solubility, and to provide a method for producing the same. According to the present invention, the crystal of an amino acid salt of HMB can be precipitated by dissolving an amorphous amino acid salt of HMB in a solvent containing alcohol and stirring or allowing the solvent to left stand. In addition, the crystal of an amino acid salt of HMB can be precipitated by concentrating an aqueous HMB solution of an amino acid salt which has a pH of 2.5 to 11.0.

Abstract: Provided is a composition for inhibiting fat formation and reducing body fat, the composition including hydrangenol as an active ingredient. The composition of the present disclosure reduces fat accumulation in adipocytes, reduces phosphorylation of mammalian target of rapamycin (mTOR), and increases phosphorylation of forkhead box O1 (FoxO1), and finally, leading to reduction of an expression level of peroxisome proliferator-activated receptor gamma y (PPAR), and as a result, the composition inhibits formation of triglyceride in adipocytes to exhibit an anti-obesity effect. Accordingly, the composition including hydrangenol disclosed herein as an active ingredient may be usefully applied to the fields of health functional foods or cosmetics for inhibiting fat formation.

Abstract: An object of the present invention is to provide a non-solvate crystal of eucomic acid having a low methanol content and excellent fluidity, and a method for producing the same. The present invention can provide a non-solvate crystal of eucomic acid having a low methanol content and excellent fluidity by drying a methanol solvate crystal of eucomic acid.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of muscle disease comprising a Panax ginseng berry extract as an active ingredient. The composition of the present invention alleviates the decrease in muscle weight and muscle fiber cross-sectional area caused by muscle atrophy, and reduces the increase in expression of MuRF-1 (Muscle RING-finger protein-1) and atrogin-1, which are involved in proteolysis of muscle proteins, so that it can be effectively used to prevent, ameliorate or treat muscle disease.

Abstract: An object of the present invention is to provide a crystal of 3?-sialyllactose (hereinafter, referred to as 3SL), which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a process for producing the same. The present invention relates to a 3SL sodium salt n-hydrate (wherein n represents any number of 0 to 9, and when n is 0, it is referred to as 3SL sodium salt anhydrate) and a process for producing the same.

Abstract: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d'Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent.

Abstract: It is an objective of the present invention to provide a composition that is sufficiently safe to allow daily ingestion and that has an ability to promote the secretion of s-IgA into saliva in a continuous and age-independent manner. The above objective is achieved by the composition for promoting secretion of secretory IgA, comprising as an active ingredient Okinawa mozuku-derived fucoidan with a recommended daily intake of 1,000 mg or more. The composition has the mucosal immunostimulatory effect, anti-infection effect or anti-allergy effect and is expected to be used for ameliorating, mitigating, suppressing, treating or preventing diseases or symptoms on which these effects are expected to work, such as bacterial infection, viral infection, protozoan infection, food allergy, pollenosis, gastritis, enteritis, diarrhea, ulcerative colitis, rhinitis, bronchitis, bronchial asthma, Löffler's syndrome and stomatitis, as well as any symptoms resulting therefrom.

Abstract: The present invention provides a medium for inducing the differentiation of stem cells into mesodermal cells, the medium comprising a ROCK inhibitor, a bone morphogenetic protein (BMP), a fibroblast growth factor (FGF), and activin. The present invention also provides a method for producing mesodermal cells from stem cells using the medium, and method for producing cardiac progenitor cells or myocardiocytes from stem cells using the medium. The present invention furthermore provides a composition for assisting the induction of differentiation of stem cells into mesodermal cells, the composition comprising a ROCK inhibitor, a BMP, an FGF, and activin. The present invention additionally provides cell groups obtained by the above methods.

Abstract: Disclosed is a scaffold for living donor transplantation, which includes sintered bioglass and a biocompatible polymer and has improved properties using a 3D printer through a fused deposition modeling process.

Abstract: Provided is a hyaluronate fiber, and more particularly to a hyaluronate fiber, suitable for use in a surgical suture, a filler for cosmetic surgery, a lifting thread, a tissue-engineering scaffold, etc., and a method of manufacturing the same. Further, a method of manufacturing the hyaluronate fiber through melt spinning is provided, which includes (a) controlling the water content of a hyaluronate having a weight average molecular weight of 500˜3,000 kDa to 5˜20%, (b) producing a hyaluronate fiber by placing the hyaluronate having a controlled water content in a melt-spinning apparatus and performing heating to 150˜200° C. and then high-pressure spinning, and (c) hardening the surface of the hyaluronate fiber by immersing the hyaluronate fiber in an ethanol aqueous solution.

Abstract: An object of the invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentration, decreased attention, decreased judgment ability, depression, and decreased exercise performance caused thereby. According to the invention, an agent for protecting brain neuronal cells, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients as well as an agent for preventing or improving decline in brain function, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients is provided.

Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.

Abstract: The present invention relates to a composition and a healthy food product for inducing bowel movements and promoting weight loss comprising 47-57 parts by weight of a psyllium husk powder, 18-28 parts by weight of a rice bran powder, 5-6 parts by weight of a kelp powder, 4-5 parts by weight of a fructooligosaccharide, 3.5-4.5 parts by weight of chicory fiber, 3-4 parts of weight of glasswort, 2.5-3.5 parts by weight of yeast powder, 1.5-2.5 parts by weight of lactulose powder, 0.5-1.5 parts by weight of lactic acid bacteria powder, 0.05-0.15 parts by weight of complex amino acid, 0.4-0.6 parts by weight of Aloe arborescens, and 0.5-1.5 parts by weight of garlic powder. The composition and health food product for inducing bowel movements and promoting weight loss of the present invention comprise nutritional ingredients such as vegetable dietary fiber, vitamins, minerals, etc. which feed beneficial intestinal bacteria.